>16 July: CordenPharma Invests €900m in Transformational Peptide Platform Expansion. Read Press Release: https://lnkd.in/enqc-t8b We are pleased to announce a record investment of ~€900m over the next 3 years in expanding our peptide platform, both at our Colorado, US site and in Europe. The expansions, covering both existing facilities and new constructions, will meet the pharmaceutical industry’s most stringent quality and technical standards for short and long peptide manufacturing, including BLA requirements. Our CordenPharma Colorado, US site expansion involves the planned construction of a new large-scale peptide manufacturing facility, and an additional increase in manufacturing trains in the existing facility. This is the result of rapidly increasing demand in the Diabetes and Obesity Glucagon-like Peptide 1 (GLP-1) agonist medications market, and comes off the back of multiple, long-term, multiyear contracts totaling ~€3bn, with potential upsides. The European expansion centers on the construction of a new state-of-the-art greenfield facility, with the aim of creating additional Peptide capacity to serve customers from initial early clinical to late-stage commercial manufacturing. These major expansion plans will act as the driving force behind our €1bn sales target for our Peptide Platform by 2028, reinforcing CordenPharma as a market leader in the integrated supply of small to large-scale services from APIs to Drug Products (for both Injectable and Oral Peptides). Dr. Michael Quirmbach, President & CEO of the CordenPharma Group comments: “These investments will profoundly strengthen our ability to provide valuable and much needed support to innovators for the benefit of patients. We are honored by the trust our customers have placed in us to deliver expert outsourcing for large multiyear contracts.” Dr. Signe Michel, Managing Director at Astorg comments: “We are proud of what Michael and the CordenPharma team have achieved through their striving for operational excellence, customer service and ambitious growth. We are excited about the opportunities ahead and to further strengthen the company’s peptide offering across the full drug lifecycle and value chain.” Judith Charpentier, Co-Head Flagship Fund and Head of Healthcare at Astorg comments: “CordenPharma has a unique opportunity to reinforce its leadership position in peptides with unmatched capacity and performance in large scale manufacturing. With the company’s proven track record and our investor experience in pharmaceutical services, we feel confident that our latest commitment will help the company seize this opportunity.” #CordenPharma #cdmo #peptides #GLP1s #diabetes #obesity #peptideagonists #oralpeptides #injectables #pharmamanufacturing #pharmaceuticals
Steven Kasok
2mo
Absolutely outstanding. Great work by the entire CordenPharma organization in earning the trust and confidence of our customers. Looking forward to bringing this capacity online and continuing to meet the needs of patients.
What a journey since ICIG started 20 years ago!
Monika Brazda
2mo
Great news for Basel Area!
Ahmed Umar
2mo
Keep growing
Great news!
Fantastic!
Executive Director at The Charles Gates Biomanufacturing Facility - CU Anschutz
2moGreat to see more manufacturing investment in Colorado!